| Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment E Resetkova, JS Reis-Filho, RK Jain, R Mehta, MA Thorat, H Nakshatri, ... Breast cancer research and treatment 123, 97-108, 2010 | 224 | 2010 |
| FOXA1 is an independent prognostic marker for ER-positive breast cancer RJ Mehta, RK Jain, S Leung, J Choo, T Nielsen, D Huntsman, H Nakshatri, ... Breast cancer research and treatment 131, 881-890, 2012 | 161 | 2012 |
| Control of EVI-1 oncogene expression in metastatic breast cancer cells through microRNA miR-22 JB Patel, HN Appaiah, RM Burnett, P Bhat-Nakshatri, G Wang, R Mehta, ... Oncogene 30 (11), 1290-1301, 2011 | 153 | 2011 |
| Atypical ductal hyperplasia: interobserver and intraobserver variability RK Jain, R Mehta, R Dimitrov, LG Larsson, PM Musto, KB Hodges, ... Modern Pathology 24 (7), 917-923, 2011 | 138 | 2011 |
| High‐level expression of forkhead‐box protein A1 in metastatic prostate cancer RK Jain, RJ Mehta, H Nakshatri, MT Idrees, SS Badve Histopathology 58 (5), 766-772, 2011 | 87 | 2011 |
| Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models Y Gökmen-Polar, Y Liu, RA Toroni, KL Sanders, R Mehta, S Badve, ... Breast cancer research and treatment 136, 673-682, 2012 | 82 | 2012 |
| Extrathoracic metastases of thymic origin: a review of 35 cases T Vladislav, RK Jain, R Alvarez, RJ Mehta, Y Gökmen-Polar, KA Kesler, ... Modern Pathology 25 (3), 370-377, 2012 | 82 | 2012 |
| PHLDA1 is a crucial negative regulator and effector of Aurora A kinase in breast cancer EO Johnson, KH Chang, Y de Pablo, S Ghosh, R Mehta, S Badve, K Shah Journal of cell science 124 (16), 2711-2722, 2011 | 82 | 2011 |
| Cancer survivorship and models of survivorship care: a review KD Miller, M Pandey, R Jain, R Mehta American Journal of Clinical Oncology 38 (6), 627-633, 2015 | 70 | 2015 |
| Genomic and immunohistochemical analysis of adenosquamous carcinoma of the breast FC Geyer, MBK Lambros, R Natrajan, R Mehta, A Mackay, K Savage, ... Modern Pathology 23 (7), 951-960, 2010 | 61 | 2010 |
| WHO types A and AB thymomas: not always benign RK Jain, RJ Mehta, JD Henley, KA Kesler, PJ Loehrer, S Badve Modern Pathology 23 (12), 1641-1649, 2010 | 52 | 2010 |
| Clinical characterization of colitis arising from anti-PD-1 based therapy DY Wang, MJ Mooradian, DW Kim, NJ Shah, SE Fenton, RM Conry, ... Oncoimmunology 8 (1), e1524695, 2019 | 50 | 2019 |
| Personalized medicine: the road ahead R Mehta, RK Jain, S Badve Clinical breast cancer 11 (1), 20-26, 2011 | 49 | 2011 |
| Loss of ERα and FOXA1 expression in a progression model of luminal type breast cancer: insights from PyMT transgenic mouse model K McCune, R Mehta, M Thorat, S Badve, H Nakshatri Oncology reports 24, 1233-1239, 2010 | 38 | 2010 |
| An open-label, single-arm pilot study of EUS-guided brachytherapy with phosphorus-32 microparticles in combination with gemcitabine+/-nab-paclitaxel in unresectable locally … MS Bhutani, JB Klapman, R Tuli, G El-Haddad, S Hoffe, FCL Wong, ... Endoscopic Ultrasound 9 (1), 24-30, 2020 | 28 | 2020 |
| Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers ES Tan, B Cao, J Kim, TE Al‐Toubah, R Mehta, BA Centeno, RD Kim Cancer 127 (8), 1293-1300, 2021 | 27 | 2021 |
| Pretreatment CT and 18F‐FDG PET‐based radiomic model predicting pathological complete response and loco‐regional control following neoadjuvant … A Rishi, GG Zhang, Z Yuan, AJ Sim, EY Song, EG Moros, ... Journal of Medical Imaging and Radiation Oncology 65 (1), 102-111, 2021 | 24 | 2021 |
| Differential subcellular expression of protein kinase C betaII in breast cancer: correlation with breast cancer subtypes Y Gökmen-Polar, R Mehta, S Tuzmen, S Mousses, MA Thorat, ... Breast cancer research and treatment 124, 327-335, 2010 | 24 | 2010 |
| ITF2 is a target of CXCR4 in MDA-MB-231 breast cancer cells and is associated with reduced survival in estrogen receptor-negative breast cancer H Appaiah, P Bhat-Nakshatri, R Mehta, M Thorat, S Badve, H Nakshatri Cancer biology & therapy 10 (6), 600-614, 2010 | 24 | 2010 |
| A phase 1/2 trial of ibrutinib in combination with pembrolizumab in patients with mismatch repair proficient metastatic colorectal cancer DW Kim, E Tan, JM Zhou, MJ Schell, M Martinez, J Yu, E Carballido, ... British Journal of Cancer 124 (11), 1803-1808, 2021 | 23 | 2021 |
nakshatri*Professor, Indiana University School of Medicine在 iupui.edu 的电子邮件经过验证
